Ontario Institute for Cancer Research (Oicr)

Ontario Institute for Cancer Research

Melanie Spears

John Bartlett

Paul Boutros

Paul M Krzyzanowski

Marsela Braunstein

Fouad Yousif

John M S Bartlett

Irina Kalatskaya

Lincoln Stein

John Ms Bartlett

Paul M Krzyzanowksi

The invention features methods, devices, and kits for predicting the responsiveness of a cancer patient (e.g., a breast cancer patient, such as a grade 1, 2, or 3 breast cancer patient) to anthracycline treatment by determining the expression levels of four chromosomal instability (CIN) genes including HDGF, KIAA0286, RFC4, and MSH6, collectively referred to as CIN4. Patients that have a low CIN4 score benefit from anthracycline treatment compared patients with a high CIN4 score.

Methods and devices for predicting anthracycline treatment efficacy

There is provided herein a method for determining a likelihood of resistance to anthracyclin, or poor survival, in a patient with cancer by identifying upregulation of at least one histone gene in the patient.

Targeting the histone pathway to detect and overcome anthracyclin resistance

Growing community of inventors

Etobicoke, Canada

Melanie Spears